Balyasny Asset Management LLC Ligand Pharmaceuticals Inc Transaction History

Balyasny Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$107.38 - $129.34 $552,684 - $665,712	-5,147 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $545,221 - $733,293	5,147 New	5,147 $647,000
Q4 2018 Feb 14, 2019	SELL	$128.36 - $272.13 $713,681 - $1.51 Million	-5,560 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$211.18 - $274.49 $401,875 - $522,354	1,903 Added 52.04%	5,560 $1.53 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $551,365 - $760,582	3,657 New	3,657 $758,000
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $553,873 - $634,477	-4,315 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $521,726 - $595,211	4,315	4,315 $587,000

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.1B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.